TP53 and acquired factor X deficiency: Both AFX and PDS are characterized by an extremely high tumor mutational burden (TMB), surpassing even that of SCC and melanoma cases [33,38], which may be attributable to chronic UV-associated DNA damage leading to the emergence of characteristic mutations in TP53 and CDKN2A/B in many affected patients [39].